Targeting Phosphoinositide-3-kinase-delta with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease
Overview
Authors
Affiliations
Rationale: Patients with chronic obstructive pulmonary disease (COPD) show a poor response to corticosteroids. This has been linked to a reduction of histone deacetylase-2 as a result of oxidative stress and is reversed by theophylline.
Objectives: To determine the role of phosphoinositide-3-kinase-delta (PI3K-δ) on the development of corticosteroid insensitivity in COPD and under oxidative stress, and as a target for theophylline.
Methods: Corticosteroid sensitivity was determined as the 50% inhibitory concentration of dexamethasone on tumor necrosis factor-α-induced interleukin-8 release in peripheral blood mononuclear cells from patients with COPD (n = 17) and compared with that of nonsmoking (n = 8) and smoking (n = 7) control subjects. The effect of theophylline and a selective PI3K-δ inhibitor (IC87114) on restoration of corticosteroid sensitivity was confirmed in cigarette smoke-exposed mice.
Measurements And Main Results: Peripheral blood mononuclear cells of COPD (50% inhibitory concentration of dexamethasone: 156.8 ± 32.6 nM) were less corticosteroid sensitive than those of nonsmoking (41.2 ± 10.5 nM; P = 0.018) and smoking control subjects (47.5 ± 19.6 nM; P = 0.031). Corticosteroid insensitivity and reduced histone deacetylase-2 activity after oxidative stress were reversed by a non-selective PI3K inhibitor (LY294002) and low concentrations of theophylline. Theophylline was a potent selective inhibitor of oxidant-activated PI3K-δ, which was up-regulated in peripheral lung tissue of patients with COPD. Furthermore, cells with knock-down of PI3K-δ failed to develop corticosteroid insensitivity with oxidative stress. Both theophylline and IC87114, combined with dexamethasone, inhibited corticosteroid-insensitive lung inflammation in cigarette-smoke-exposed mice in vivo.
Conclusions: Inhibition of oxidative stress dependent PI3K-δ activation by a selective inhibitor or theophylline provides a novel approach to reversing corticosteroid insensitivity in COPD.
Tahri S, Fakhfakh R, Bahloul E, Charfi S, Sellami K, Hachicha H Arch Dermatol Res. 2025; 317(1):479.
PMID: 39988616 DOI: 10.1007/s00403-025-03864-1.
Manrui L, Xu Y, Liu J, Zhang X, Yuan R, Sun Y Cell Mol Life Sci. 2025; 82(1):87.
PMID: 39985589 PMC: 11846823. DOI: 10.1007/s00018-025-05601-3.
Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders.
Ashique S, Mishra N, Mantry S, Garg A, Kumar N, Gupta M Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):417-448.
PMID: 39196392 DOI: 10.1007/s00210-024-03392-1.
Emerging roles and therapeutic implications of HDAC2 and IL-17A in steroid-resistant asthma.
Ouyang L, Su G, Quan J, Xiong Z, Lai T Chin Med J Pulm Crit Care Med. 2024; 1(2):108-112.
PMID: 39170824 PMC: 11332885. DOI: 10.1016/j.pccm.2023.04.003.
A narrative review of theophylline: is there still a place for an old friend?.
Scurek M, Brat K J Thorac Dis. 2024; 16(5):3450-3460.
PMID: 38883616 PMC: 11170423. DOI: 10.21037/jtd-23-1781.